Clinical Trial Update: Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A) [Phase 2]

View source ↗

Summary

Phase 2 MATCH subprotocol evaluating afatinib for cancers with EGFR genetic alterations; results have been posted and the trial is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Multiple Myeloma
• Solid Tumors

Drugs mentioned

• Afatinib (afatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-12-10